Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCardiaBCDA -0.91%23 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates BCDA with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 841 Biotechnology companies, BioCardia ranks worse than 118905.95% on this metric.
The historical rank and industry rank for BioCardia's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, BioCardia's highest Days Sales Outstanding was 477.02. The lowest was 46.89. And the median was 101.01.
BCDA's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
BioCardia's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
BioCardia (NAS:BCDA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BioCardia Days Sales Outstanding Related Terms
BioCardia Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BioCardia's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCDA vs ZIVO, CYCN, LPCN: Days Sales Outstanding Comparison
For the Biotechnology subindustry, BioCardia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BioCardia's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia (BCDA) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BioCardia and its competitors. Over the past decade, BioCardia's Days Sales Outstanding has ranged from 46.89 to 477.02. According to the industry distribution chart, BioCardia ranks #999999 out of 841 companies in the Biotechnology industry.
Is BioCardia's Days Sales Outstanding too high?
BioCardia's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 46.89 to a high of 477.02. Based on the distribution chart, BioCardia ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioCardia has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's Days Sales Outstanding compare to ZIVO and CYCN?
According to the Biotechnology industry distribution chart, BioCardia ranks #999999 out of 841 companies for Days Sales Outstanding. This places BioCardia in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, BioCardia's own Days Sales Outstanding has ranged from 46.89 to 477.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BioCardia and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCardia's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (BCDA) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. BioCardia's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BioCardia (BCDA), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
23GF Score
Get the complete analysis for BCDA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCDA has been successfully added to your 
